MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务。

Milrinone

CAS No. : 78415-72-2

MCE 国际站：Milrinone

产品活性：Milrinone 是 PDE3 抑制剂，也是一种强心药、血管舒张药。

研究领域：Metabolic Enzyme/Protease

作用靶点：Phosphodiesterase (PDE)

In Vitro: Milrinone (1 µM) increases PKA activity in hypoxic myocytes to normoxic levels. Milrinone (50 nM) normalizes TP receptor sensitivity in hypoxic myocytes by restoring PKA-mediated regulatory TP receptor phosphorylation. Milrinone significantly reduces NE-induced vasoconstriction, attenuating both NE sensitivity and maximal tension generation. Inhibition of ATP-sensitive K⁺ channels or voltage-gated K⁺ channels do not prevent the milrinone-induced attenuation of NE responses.

In Vivo: Milrinone (1 μg/kg/min, i.v.) significantly reduces PAP, PVR (−18.96 ± 1.7%), and LAP (−26.03 ± 2.3%) in congestive heart failure (CHF) rats. Milrinone (1 mg/mL, inhalation) results in a near-maximal reduction of PAP without significant effects on AP, decreases pulmonary artery pressure similarly in a larger collective of CHF rats. Milrinone inhalation selectively increases cAMP but not cGMP plasma concentrations in both groups. Repeated milrinone inhalations even reduce lung wet/dry weight ratio. Milrinone (49.5 μg) largely shifts the ESPVR upwards and significantly increases end-systolic pressure (ESP(0.08)) and the systolic pressure-volume area (PVA(0.08)) at a mid-range LV volume (0.08 mL/g myocardium). Milrinone also slightly decreases LV ESP(ESV) and decreased Ea.

相关产品：Covalent Screening Library Plus  |  Drug Repurposing Compound Library Plus  |  FDA-Approved Drug Library Plus  |  FDA-Approved Drug Library Mini  |  Bioactive Compound Library Plus  |  Metabolism/Protease Compound Library  |  FDA-Approved Drug Library  |  Drug Repurposing Compound Library  |  Covalent Screening Library  |  Anti-Cardiovascular Disease Compound Library  |  Anti-COVID-19 Compound Library  |  NMPA-Approved Drug Library  |  FDA Approved & Pharmacopeial Drug Library  |  Anti-Alzheimer's Disease Compound Library  |  Drug-Induced Liver Injury (DILI) Compound Library  |  Neurodegenerative Disease-related Compound Library  |  Rare Diseases Drug Library  |  Anti-Colorectal Cancer Compound Library   |  Children’s Drug Library  |  Human Metabolite Library  |  Heterocyclic Compound Library  |  Off-patent Drug Library  |  Cirsimarin  |  PDE11-IN-1  |  Enpp-1-IN-2  |  PAT-347  |  Vardenafil-d₅  |  Bay 60-7550  |  Deltarasin hydrochloride  |  HA155  |  Apremilast  |  Enpp-1-IN-6  |  Roflumilast  |  RS-25344 hydrochloride  |  PDE4-IN-6  |  Sp-cAMPS  |  ITI-214  |  Irsenontrine maleate  |  Lodenafil  |  Osoresnontrine  |  Deltasonamide 2  |  PF-07038124  |  Ziritaxestat  |  ATX inhibitor 22  |  Milrinone-d₃  |  Avanafil-¹³C,d₃  |  MT-3014  |  ATX inhibitor 19  |  Homo Sildenafil-d₅  |  Furamidine  |  PDE4-IN-12  |  Enpp-1-IN-8

热门产品线：重组蛋白  |  化合物库  |  天然产物  |  荧光染料  |  PROTAC  |  同位素标记物  |  寡核苷酸  |  抗体  |  点击化学

Trending products：Recombinant Proteins  |  Bioactive Screening Libraries  |  Natural Products  |  Fluorescent Dye  |  PROTAC  |  Isotope-Labeled Compounds  |  Oligonucleotides  |  Antibodies  |  Click Chemistry

货号: HY-14252

品牌介绍:
•   MCE (MedChemExpress) 拥有200 多种全球独家化合物库，我们致力于为全球科研客户提供前沿最全的高品质小分子活性化合物；
•   50,000 多种高选择性抑制剂、激动剂涉及各热门信号通路及疾病领；
•   产品种类涵盖各种重组蛋白，多肽，常用试剂盒 ，更有 PROTAC、ADC 等特色产品，广泛应用于新药研发、生命科学等科研项目；
•   提供虚拟筛选，离子通道筛选，代谢组学分析检测分析，药物筛选等专业技术服务；
•   设有专业的实验中心和严格的质控、验证体系；
•   提供 LC/MS、NMR、HPLC、手性分析、元素分析等各项质检报告，确保产品的高纯度、高品质；
•   产品的生物活性多经各国客户实验验证；
•   Nature, Cell, Science 等多种顶级期刊及制药专利收录了MCE客户的科研成果；
•   专业团队跟踪最新的制药及生命科学研究进展，为您提供全球最新的活性化合物；
•   与世界各大制药公司及知名科研机构建立了长期的合作。